Search results for "TNF"

showing 10 items of 161 documents

The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducin…

2007

Abstract Context: We previously showed that BAG3 protein, a member of the BAG (Bcl-2-associated athanogene) co-chaperone family, modulates apoptosis in human leukemias. The expression of BAG3 in other tumor types has not been extensively investigated so far. Objective: The objective of this study was to analyze BAG3 expression in thyroid neoplastic cells and investigate its influence in cell apoptotic response to TNF-related apoptosis-inducing ligand (TRAIL). Design, Setting, and Patients: We investigated BAG3 expression in human thyroid carcinoma cell lines, including NPA, and the effect of BAG3-specific small interfering RNA on TRAIL-induced apoptosis in NPA cells. Subsequently, we analyz…

medicine.medical_specialtySmall interfering RNAProgrammed cell deathEndocrinology Diabetes and MetabolismClinical BiochemistryApoptosisBiologyBiochemistryThyroid carcinomaTNF-Related Apoptosis-Inducing LigandEndocrinologyWestern blotInternal medicineCell Line TumormedicineHumansThyroid NeoplasmsRNA Small InterferingThyroid cancerAdaptor Proteins Signal Transducingmedicine.diagnostic_testDose-Response Relationship DrugBiochemistry (medical)ThyroidCarcinomamedicine.diseaseImmunohistochemistryEndocrinologymedicine.anatomical_structureApoptosisCancer researchTumor necrosis factor alphaApoptosis Regulatory Proteins
researchProduct

AB0467 EFFECTIVENESS OF GOLIMUMAB AFTER TNF-INHIBITOR FAILURE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, OR AXIAL SPONDYLOART…

2021

Background:Golimumab showed trial efficacy in subjects with active rheumatoid arthritis (RA) previously treated with TNF-inhibitors (TNFi); no trial data are available for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).Objectives:To assess the effectiveness of golimumab after TNFi failure in patients with RA, PsA, or axSpA in a real-world setting.Methods:GO-BEYOND-Italy is an ongoing, multicenter, prospective, observational study of RA, PsA, or axSpA patients starting golimumab after TNFi failure. Patients were enrolled between July 2017 and December 2019, and followed for 1 year, with evaluations at 3, 6, and 12 months. This interim analysis estimates the effectiveness after…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologymedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyInfliximabGolimumabTNF inhibitorEtanerceptPsoriatic arthritisRheumatologyRheumatoid arthritisInternal medicinemedicineAdalimumabImmunology and AllergyAxial spondyloarthritisbusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

Effects of the static magnetic field generated by a 1,5 T MRI unit on TNF-a release and TNF-receptor II expression of human monocyes

2008

monocytes TNF-a MRI
researchProduct

Osteoprotegerin: multiple partners for multiple functions.

2013

Osteoprotegerin (OPG) is an essential secreted protein in bone turnover due to its role as a decoy receptor for the Receptor Activator of Nuclear Factor-kB ligand (RANKL) in the osteoclasts, thus inhibiting their differentiation. However, there are additional ligands of OPG that confer various biological functions. OPG can promote cell survival, cell proliferation and facilitates migration by binding TNF-related apoptosis inducing ligand (TRAIL), glycosaminoglycans or proteoglycans. A large number of in vitro, pre-clinical and clinical studies provide evidences of OPG involvement in vascular, bone, immune and tumor biology. This review describes an overview of the different OPG ligands regu…

musculoskeletal diseasesCell SurvivalEndocrinology Diabetes and MetabolismImmunologyOsteoclastsGeneral Biochemistry Genetics and Molecular BiologyTNF-Related Apoptosis-Inducing LigandOsteoprotegerinImmunology and AllergyAnimalsHumansCell adhesionReceptorCell ProliferationbiologyActivator (genetics)Cell growthChemistryRANK LigandOsteoprotegerinCell DifferentiationIn vitroCell biologyBiochemistryRANKLbiology.proteinDecoyCytokinegrowth factor reviews
researchProduct

Nutritional properties and plausible benefits of Pearl millet (Pennisetum glaucum) on bone metabolism and osteoimmunology : a mini-review

2020

Bone is a hard connective tissue that undergoes a systematic renewal. This highly dynamic organ is made up of four different types of cells, however, bone formation is commonly attributed to osteoblasts and bone resorption to osteoclasts. Bone tissue formation occurs during embryonic development and in certain post-birth pathological conditions. The immune system could influence the functions of bone cells, and the crosstalk between hematopoietic, immune, and bone cells is known as osteoimmunology. Indeed, cytokines produced by immune cells, including TNF-α and IL-6, are critically implicated in bone pathogenesis. It is well established that diet plays an important role in bone health and f…

osteoimmunologyOsteoimmunologyfood and beveragesosteoblastsengineering.materialBiologybiology.organism_classificationBone remodelingMini reviewosteoclastsnutrientsTNF-αengineeringFood sciencePM whole grainsPearlPennisetumpolyphenols
researchProduct

TRAIL acts synergistically with iron oxide nanocluster-mediated magneto- and photothermia

2019

International audience; Targeting TRAIL (Tumor necrosis factor (TNF)-Related Apoptosis-Inducing Ligand) receptors for cancer therapy remains challenging due to tumor cell resistance and poor preparations of TRAIL or its derivatives. Herein, to optimize its therapeutic use, TRAIL was grafted onto iron oxide nanoclusters (NCs) with the aim of increasing its pro-apoptotic potential through nanoparticle-mediated magnetic hyperthermia (MHT) or photothermia (PT). Methods: The nanovector, NC@TRAIL, was characterized in terms of size, grafting efficiency, and potential for MHT and PT. The therapeutic function was assessed on a TRAIL-resistant breast cancer cell line, MDA-MB-231, wild type (WT) or T…

photothermal therapyCell SurvivalMedicine (miscellaneous)TRAIL02 engineering and technologyFerric CompoundsFlow cytometryTNF-Related Apoptosis-Inducing LigandCell membrane03 medical and health sciences0302 clinical medicineMicroscopy Electron TransmissionCell surface receptorCell Line Tumormedicine[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biologymagnetic hyperthermiaReceptorPharmacology Toxicology and Pharmaceutics (miscellaneous)ComputingMilieux_MISCELLANEOUSchemistry.chemical_classificationCell Deathmedicine.diagnostic_testTumor Necrosis Factor-alphairon oxide nanoclustersapoptosisHyperthermia InducedFlow Cytometry021001 nanoscience & nanotechnology3. Good healthMagnetic hyperthermiamedicine.anatomical_structurechemistryTransferrinApoptosis030220 oncology & carcinogenesisCancer research[SDV.IB]Life Sciences [q-bio]/BioengineeringTumor necrosis factor alpha0210 nano-technologyResearch Paper
researchProduct

Isolement et caractérisation de saponosides extraits de deux plantes médicinales : Cyclamen africanum, Zygophyllum cornutum et évalution de leur acti…

2014

The appearance of several diseases, such as cancer, diabetes, high blood pressure and spread of infections mutagenic virus type can be linked to the quality and lifestyle that we lead today. Indeed, several studies on the factors triggering these so-called "morbid" long-or short-term illnesses are related to stress and quality of food consumed, whether of plant and animal origin. These diseases are becoming a common occurrence, they affect different races and all classes of society. According ethnobotanical research, naturally occurring substances, allowed civilizations to survive deadly diseases. For example, we thus find references to periods of malarial fever in China and one of the symp…

protéines réponse inflammatoire (PRI)[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMass spectrometry1D and 2D NMRZygophyllum cornutumMédiateurs pro-inflammatoire (COX-2)Anti-inflammatoires (AINS)INOSPro-inflammatory mediatorsProtein inflammatory response (PRI)Activité anti inflammatoireAnti inflammatory activitySaponins triterpeneCyclamen africanumCOX-2Spectrométrie de masseRMN 1DRMN 2DSaponines triterpéniques[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyAnti-inflammatory drugs (NSAIDs)TNF -αPGE2[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Inflammatory cytokines shape a changing DNA methylome in monocytes mirroring disease activity in rheumatoid arthritis

2019

Objective: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that mainly targets joints. Monocytes and macrophages are critical in RA pathogenesis and contribute to inflammatory lesions. These extremely plastic cells respond to extracellular signals which cause epigenomic changes that define their pathogenic phenotype. Here, we interrogated how DNA methylation alterations in RA monocytes are determined by extracellular signals. Methods: High-throughput DNA methylation analyses of patients with RA and controls and in vitro cytokine stimulation were used to investigate the underlying mechanisms behind DNA methylation alterations in RA as well as their relationship with clinic…

rheumatoid arthritis0301 basic medicine*DAS28Immunology*disease activityGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokineArthritis RheumatoidPathogenesisEpigenome03 medical and health sciences0302 clinical medicineRheumatologymedicineDAS28HumansImmunology and AllergyEpigenomics030203 arthritis & rheumatologyDNA methylationTumor Necrosis Factor-alphabusiness.industryMacrophagesMonocyteTNFaMethylationDNA Methylationmedicine.disease*rheumatoid arthritis030104 developmental biologymedicine.anatomical_structure*TNFaRheumatoid arthritis*DNA methylationImmunologyDNA methylationLeukocytes MononuclearCytokinesTumor necrosis factor alphaInflammation Mediatorsbusinessdisease activityBiomarkersAnnals of the Rheumatic Diseases
researchProduct

Sinergismo d'azione tra protocollo riabilitativo ed anti-TNFalfa versus terapia biologica

2012

La spondilite anchilosante è una malattia infiammatoria cronica ad eziologia sconosciuta che colpisce prevalentemente lo scheletro assile ma che può coinvolgere anche le entesi periferiche. Presso l'ambulatorio dell'U.O.C. di Riabilitazione dell'A.U.O.P. "Paolo Giaccone" di Palermo, in diciotto mesi (Aprile 2011-Maggio 2012) sono stati arruolati 24 soggetti (6 donne- 18 uomini). affetti da Spondilite Anchilosante HLA B27 diagnosticata secondo i criteri europei. Il presente studio ha mostrato efficacia nel trattamento di pazienti con SA mediante un progetto-programma riabilitativo mirato e specifico per distretto articolare. Svolgere con regolarità e costanza l'esercizio terapeutico in assoc…

riabilitazione spondilite anchilosante anti-TNFalfaSettore MED/34 - Medicina Fisica E Riabilitativa
researchProduct

Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in De…

2020

Background: Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. Objective: To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and ustekinumab used for the treatment of moderate to severe psoriasis in patients included in the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. Methods: The incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events for each drug, using methotrexate as reference, were determined by means of a prospective cohort. Results: O…

safetyAdultMalemedicine.medical_specialtyTime Factorsbiologic agentsprospective cohortlong-term follow-upDermatologyimmunosuppressive agentsanti-inflammatory agentsCohort Studies030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicinePsoriasisUstekinumabmedicineAdalimumabHumansPsoriasisRegistriesAdverse effectProspective cohort studyAgedbusiness.industryregistriespsoriasis/drug therapyanti-TNFMiddle Agedmedicine.diseaseInfliximabBiological TherapySpain030220 oncology & carcinogenesispharmacovigilanceadverse effectsSecukinumabFemaleApremilastbusinessmedicine.drugJournal of the American Academy of Dermatology
researchProduct